Literature DB >> 34709479

Serum irisin levels in patients with myasthenia gravis.

Sheng-Nan Zhang1, Qi Li1, Qiu-Xia Zhang1, Tian-Xiao Gao1, Sheng-Hui Chang1, Da-Qi Zhang2, Lin-Jie Zhang1, Li Yang3.   

Abstract

OBJECTIVE: Myasthenia gravis (MG) is an autoimmune disorder whose main symptoms are muscle weakness and fatigue. Irisin is a novel skeletal muscle-derived myokine participating in several physiological and pathological processes. The initial objective of the project was to explore serum levels of irisin in patients with MG, as well as its correlation with disease severity.
METHODS: We retrospectively evaluated serum levels of irisin in 77 MG patients and 57 healthy controls (HCs) by enzyme-linked immunosorbent assay. Further, clinical parameters were measured properly.
RESULTS: Serum irisin levels were significantly elevated in MG patients compared with HCs (p < 0.001). Furthermore, serum irisin levels were associated with the myasthenia gravis activities of daily living score in ocular myasthenia gravis (OMG) patients (r = 0.476, p = 0.004), but there was no relationship to be considered of any relevant value in generalized myasthenia gravis (GMG) patients. Acetylcholine receptor antibody-positive MG patients had higher serum irisin levels compared with HCs. Thymoma, endotracheal intubation, or intensive care unit treatments subsequently were not found to have effect on serum levels of irisin, but tendencies of increase were observed in negative ones.
CONCLUSIONS: Serum irisin levels were elevated in patients with MG, suggesting its possible involvement in MG. And irisin is expected to be a signal to evaluate the activities of daily living of OMG patients, while its effect needs further study.
© 2021. Fondazione Società Italiana di Neurologia.

Entities:  

Keywords:  ELISA; Irisin; Myasthenia gravis; Serum

Mesh:

Substances:

Year:  2021        PMID: 34709479     DOI: 10.1007/s10072-021-05652-x

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.830


  26 in total

Review 1.  Physiology and role of irisin in glucose homeostasis.

Authors:  Nikolaos Perakakis; Georgios A Triantafyllou; José Manuel Fernández-Real; Joo Young Huh; Kyung Hee Park; Jochen Seufert; Christos S Mantzoros
Journal:  Nat Rev Endocrinol       Date:  2017-02-17       Impact factor: 43.330

Review 2.  Myasthenia gravis.

Authors:  Nils Erik Gilhus; Socrates Tzartos; Amelia Evoli; Jacqueline Palace; Ted M Burns; Jan J G M Verschuuren
Journal:  Nat Rev Dis Primers       Date:  2019-05-02       Impact factor: 52.329

3.  [Glucose and lipid metabolic disorders in myasthenia gravis patients and its mechanisms].

Authors:  L J Li; Y Z Guan; F Lü; Y W Song; X J Xu; Y Jiang; O Wang; W B Xia; X P Xing; M Li
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2018-02-27

4.  FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise.

Authors:  Joo Young Huh; Grigorios Panagiotou; Vassilis Mougios; Mary Brinkoetter; Maria T Vamvini; Benjamin E Schneider; Christos S Mantzoros
Journal:  Metabolism       Date:  2012-09-25       Impact factor: 8.694

5.  Physical exercise in myasthenia gravis is safe and improves neuromuscular parameters and physical performance-based measures: A pilot study.

Authors:  Elisabet Westerberg; Carl Johan Molin; Ida Lindblad; Margareta Emtner; Anna Rostedt Punga
Journal:  Muscle Nerve       Date:  2017-04-02       Impact factor: 3.217

6.  Irisin-mediated protective effect on LPS-induced acute lung injury via suppressing inflammation and apoptosis of alveolar epithelial cells.

Authors:  Lei Shao; Di Meng; Fei Yang; Haibo Song; Dongqi Tang
Journal:  Biochem Biophys Res Commun       Date:  2017-04-07       Impact factor: 3.575

7.  A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis.

Authors:  Pontus Boström; Jun Wu; Mark P Jedrychowski; Anisha Korde; Li Ye; James C Lo; Kyle A Rasbach; Elisabeth Almer Boström; Jang Hyun Choi; Jonathan Z Long; Shingo Kajimura; Maria Cristina Zingaretti; Birgitte F Vind; Hua Tu; Saverio Cinti; Kurt Højlund; Steven P Gygi; Bruce M Spiegelman
Journal:  Nature       Date:  2012-01-11       Impact factor: 49.962

8.  Irisin Protects Against Motor Dysfunction of Rats with Spinal Cord Injury via Adenosine 5'-Monophosphate (AMP)-Activated Protein Kinase-Nuclear Factor Kappa-B Pathway.

Authors:  Xi Jiang; Zhihong Shen; Jin Chen; Chao Wang; Zhan Gao; Songling Yu; Xuefeng Yu; Lei Chen; Lexing Xu; Ziwei Chen; Wenjuan Ni
Journal:  Front Pharmacol       Date:  2020-11-16       Impact factor: 5.810

9.  Association of serum irisin with metabolic syndrome in obese Chinese adults.

Authors:  Bing Yan; Xiulin Shi; Huijie Zhang; Lingling Pan; Zhimin Ma; Suhuan Liu; Yongwen Liu; Xiaoying Li; Shuyu Yang; Zhibin Li
Journal:  PLoS One       Date:  2014-04-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.